Rare-variant association study unveils the Achilles' heel for HCC.

Abstract

In this issue of Cell Genomics, Wang, Liu, Zuo, Wang, et al.¹ investigate rare variants in hepatocellular carcinoma (HCC) by performing the first rare-variant association study (RVAS) in a Chinese population cohort. It uncovers BRCAness phenotypes associated with the NRDE2-p.N377I variant, suggesting PARP inhibitors as a promising therapeutic approach for certain HCC patients.